Back to Market Feed

Product Information

PYLERA 140-125-125 MG CAPSULE is a brand product labeled by H2-Pharma LLC, priced at $2.4278 per EA under NDC 61269038012. Its NADAC has been published 116 times since Jun 5, 2024.

FDA first approved this application on Sep 28, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

Strength

140; 125; 125 mg/1; mg/1; mg/1

Manufacturer

H2-Pharma LLC

NDC

61269038012

Classification

Brand

Dosage Form

CAPSULE

Route

ORAL

Effective Date

8/19/2026

Approval Type

New Drug (NDA)

FDA Application

NDA050786

FDA Approved

9/28/2006

TE Code

AB

On Market Since

10/1/2023

Pharmacological Classes

Bismuth
Bismuth
Nitroimidazole Antimicrobial
Nitroimidazoles
Tetracycline-class Antimicrobial
Tetracyclines

Price Statistics

The NADAC for PYLERA 140-125-125 MG CAPSULE has been published 116 times since Jun 5, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.

Current price$2.4278 per EA
All-time high$2.4364 (Mar 12, 2025)
All-time low$2.4257 (Aug 20, 2025)
52-week high$2.4290
52-week low$2.4257
Median price$2.4283
Average price$2.4300
Largest weekly change-0.3% (Apr 23, 2025)
Weeks tracked116
Tracking sinceJun 5, 2024

Price History

1W

-0.0%

1M

-0.0%

3M

-0.0%

6M

-0.0%

1Y

+0.1%

3Y

N/A

5Y

N/A

All

-0.3%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, and TETRACYCLINE HYDROCHLORIDE market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Related Drugs

Same classification

VANDAZOLE VAGINAL 0.75% GEL
Brand
00245086070•Upsher-Smith Laboratories LLC
$0.3235
per GM
LIKMEZ 500 MG/5 ML SUSPENSION
Brand
71656006675•Saptalis Pharmaceuticals LLC
$2.5999
per ML
LIKMEZ 500 MG/5 ML SUSPENSION
Brand
81033006620•Kesin Pharma Corporation
$2.6093
per ML
LIKMEZ 500 MG/5 ML SUSPENSION
Brand
71656006620•Saptalis Pharmaceuticals LLC
$2.6117
per ML
METROGEL TOPICAL 1% GEL
Brand
00299382060•Galderma Laboratories, L.P.
$6.0483
per GM
TINDAMAX 500 MG TABLET
Brand
00178850020•Mission Pharmacal Company
$13.0140
per EA
TINDAMAX 500 MG TABLET
Brand
00178850060•Mission Pharmacal Company
$13.0140
per EA
AMZEEQ 4% FOAM
Brand
69489020130•Journey Medical Corporation
$15.5415
per GM
DORYX MPC DR 60 MG TABLET
Brand
51862056012•Mayne Pharma
$18.1822
per EA
DORYX MPC DR 60 MG TABLET
Brand
51862056060•Mayne Pharma
$18.1822
per EA

Frequently asked questions

What is the NADAC price of PYLERA 140-125-125 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for PYLERA 140-125-125 MG CAPSULE, manufactured by H2-Pharma LLC, is $2.4278 per EA (NDC 61269038012), effective Aug 19, 2026.

How has the price of PYLERA 140-125-125 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for PYLERA 140-125-125 MG CAPSULE has held within roughly two percent of its current level. It has been tracked across 116 weekly CMS publications since Jun 5, 2024.

What are the highest and lowest recorded NADAC prices for PYLERA 140-125-125 MG CAPSULE?

Since Jun 5, 2024, the NADAC for PYLERA 140-125-125 MG CAPSULE has ranged from a low of $2.4257 (Aug 20, 2025) to a high of $2.4364 (Mar 12, 2025), with a median of $2.4283 per EA.

Are there cheaper alternatives to PYLERA 140-125-125 MG CAPSULE?

No other NADAC-published product currently shares the active ingredient and strength of PYLERA 140-125-125 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures PYLERA 140-125-125 MG CAPSULE?

PYLERA 140-125-125 MG CAPSULE (NDC 61269038012) is labeled by H2-Pharma LLC, and CMS classifies it as a brand product.